NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Sunbird Bio

Sunbird Bio

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://sunbirdbio.com

Last Round

Early Funding

Oct 16, 2024

Total Funding Raised

$36M

Company Overview

Sunbird Bio is a biotechnology company that develops proprietary blood-based diagnostic tests to enable earlier, more accurate diagnosis and treatment of neurological disorders and early-stage cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Usage-Based SaaS

AI Layer

Non-AI

Keywords

biotechnologydiagnostic testsneurodegenerative diseaseliquid biopsyblood-based biomarkersAPEX platformAlzheimer's diagnosticsParkinson's diagnosticsprotein biomarkerprecision medicinepatient stratificationdrug development supportclinical diagnosticsbiomarker validationnon-invasive diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sunbird Bio Comparables

Compare Sunbird Bio with similar companies based on industry and business-model similarity.

Sunbird Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
C2N Diagnostics
82%
ADmit Therapeutics
79%
ALZpath, Inc.
79%

Sunbird Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingOct 16, 2024
M&AAug 9, 2023
VC RoundMay 12, 2023
Series AOct 11, 2018

Sunbird Bio Investors

Notable investors and investment history

Sunbird Bio investors
InvestorRounds
GreatPoint VenturesSeries A
S32Early Funding
ARCH Venture PartnersSeries A
ClavystBioEarly Funding
EDBIEarly Funding
Yonghua CapitalSeries A
Rivas CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 8, 2025

    Richard Batrla appointed as the new Chief Medical Officer.

  • Oct 16, 2024

    $14M raised with EDBI and Eli Lilly leading.

Sunbird Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sunbird Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sunbird Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range32
Year Founded2021
Last FundingOct 16, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.